BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 28390962)

  • 1. In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens.
    Mezzatesta ML; La Rosa G; Maugeri G; Zingali T; Caio C; Novelli A; Stefani S
    Int J Antimicrob Agents; 2017 Jun; 49(6):763-766. PubMed ID: 28390962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study.
    Fajfr M; Louda M; Paterová P; Ryšková L; Pacovský J; Košina J; Žemličková H; Broďák M
    BMC Urol; 2017 Apr; 17(1):33. PubMed ID: 28446177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-spectrum β-lactamase-producing Enterobacteriaceae: in vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline.
    Al-Zarouni M; Senok A; Al-Zarooni N; Al-Nassay F; Panigrahi D
    Med Princ Pract; 2012; 21(6):543-7. PubMed ID: 22722224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
    Raja NS
    J Infect Public Health; 2019; 12(6):843-846. PubMed ID: 31176606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon.
    Araj GF; Jaber FA
    J Med Liban; 2012; 60(3):142-7. PubMed ID: 23198454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study.
    Cuevas O; Cercenado E; Gimeno M; Marín M; Coronel P; Bouza E;
    Diagn Microbiol Infect Dis; 2010 Jul; 67(3):251-60. PubMed ID: 20542206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
    Demir T; Buyukguclu T
    Int J Infect Dis; 2013 Nov; 17(11):e966-70. PubMed ID: 23742831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin.
    Falagas ME; Maraki S; Karageorgopoulos DE; Kastoris AC; Mavromanolakis E; Samonis G
    Int J Antimicrob Agents; 2010 Mar; 35(3):240-3. PubMed ID: 20034765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study.
    García-Rodríguez JA; Trujillano Martín I; Baquero F; Cisterna R; Gobernado M; Liñares F; Martín-Luengo F; Piédrola G
    J Chemother; 1997 Dec; 9(6):394-402. PubMed ID: 9491838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin].
    Hernández MS; García JA; Muñoz JL
    Rev Esp Quimioter; 2009 Mar; 22(1):25-9. PubMed ID: 19308743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.
    Keating GM
    Drugs; 2013 Nov; 73(17):1951-66. PubMed ID: 24202878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibility of Escherichia coli strains isolated from urine samples obtained in mainland China to fosfomycin trometamol and other antibiotics: a 9-year surveillance study (2004-2012).
    Lai B; Zheng B; Li Y; Zhu S; Tong Z
    BMC Infect Dis; 2014 Feb; 14():66. PubMed ID: 24502648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of temocillin and 15 other agents, including fosfomycin and colistin, against Enterobacteriaceae in Hong Kong.
    Ip M; Lai CK; Fung KSC; Wong KT; Zhu C; Van de Velde S; Tsang DN; Hawkey P
    Eur J Clin Microbiol Infect Dis; 2017 Dec; 36(12):2491-2494. PubMed ID: 28840351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections.
    Schito GC; Naber KG; Botto H; Palou J; Mazzei T; Gualco L; Marchese A
    Int J Antimicrob Agents; 2009 Nov; 34(5):407-13. PubMed ID: 19505803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fosfomycin: In vitro efficacy against multidrug-resistant isolates beyond urinary isolates.
    Demir T; Buyukguclu T
    J Glob Antimicrob Resist; 2017 Mar; 8():164-168. PubMed ID: 28167307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline.
    Livermore DM; Warner M; Mushtaq S; Doumith M; Zhang J; Woodford N
    Int J Antimicrob Agents; 2011 May; 37(5):415-9. PubMed ID: 21429716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
    Garau J
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.